Baseline Demographics, Physical Examinations and Data
Collection
Case record form (CRF) and
electronic data capture (EDC) are used for data collection and data
management.
Data collected at the baseline will include participants’ demographics
including date of birth, gender, education, occupation, and health
insurance, lifestyles including tobacco smoking, alcohol drinking, diet
pattern (food frequency), and time on sedentary life, systolic blood
pressure (SBP), diastolic blood pressure (DBP), heart rate, height,
weight; medical history of hypertension, diabetes mellitus and
hyperlipidemia, and current use of medications (statins,
aspirin/clopidogrel, angiotensin converting enzyme
inhibitors/angiotensin receptor blocker, β-receptor blocker, calcium
channel blockers, insulin, hypoglycemic medicine, and nitrates). Blood
pressure and heart rate were measured by pulse wave sphygmomanometer
(RBP-9000c, Shenzhen, China) for 3 times after 30 seconds interval.
Baseline laboratory blood parameters to be collected include total
cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol
(LDL-C), high density lipoprotein cholesterol (HDL-C), C-reactive
protein (CRP), homocysteine (HCY), uric acid, urea nitrogen, creatinine,
fasting plasma glucose (FPG), alanine aminotransferase (ALT), aspartate
aminotransferase (AST), total protein, albumin, lactate dehydrogenase,
hydroxybutyric acid, creatine kinase, creatine kinase isoenzyme.
Hypertension is defined as SBP≥140 mmHg or DBP≥90mmHg or current use of
anti-hypertension medications. Diabetes mellitus is defined as either
glycosylated hemoglobin ( HbA1c) ≥6.5% or FPG ≥126 mg/ dL (7.0 mmol/L)
or 2-h plasma glucose ≥200 mg/dL (11.1 mmol/L) during an oral glucose
tolerance test; or currently taking blood glucose lowering medications
or insulin. Hyperlipidemia includes the following: TC >200
mg/dL/(5.18 mmol/L); or LDL-C ≥ 130 mg/dL (3.37 mmol/L); or HDL-C
<40 mg/dL (1.04 mmol/L) in men and <50 mg/dL (1.30
mmol/L) in women; or lipoprotein a >50 mg/dL (125 nmol/L),
or persistent elevations of TG ≥ 175 mg/dL (≥ 1.97 mmol/L); or currently
receiving antilipidemic medications.